Advantages and disadvantages of lockdown (self-isolation regime) introduced during the first wave of coronaviral infection for patients with polymorbid pathology

Abstract

AIM: To study the structure of mortality not caused by coronavirus infection, in patients with polymorbid pathology during the period of self-isolation (lockdown).

MATERIALS AND METHODS: Outpatient records of 2 423 patients with polymorbid pathology (841 males and 1 582 females, aged from 18 to 99 years) were examined. The mortality and its causes during three years including a period of lockdown were investigated.

RESULTS: The overall mortality rate among patients with polymorbid pathology was 10.2% without differences in gender. The structure of the causes of death in patients with polymorbidity: cardiovascular diseases accounted for 50.8%, oncological diseases — 21%, nervous system diseases — 7.3%. During the lockdown, an increase in overall mortality by 34.3% was recorded (p < 0.05), with an increase in the number of deaths of patients with cardiovascular diseases by 19.5% (p > 0.05) (mostly patients with ischemic heart disease).

CONCLUSION: An increase in the number of deceased patients with polymorbidity during the lockdown may be due to the limitation of physical activity, of the possibility of examination and consultation by profile specialists. Taking into account the vulnerability of this group of patients, there is an urgent need to develop preventive measures when the situation recurs.

Keywords

polymorbidity / lockdown / mortality / new coronavirus infection / COVID-19

References

[1] Demograficheskaya situatsiya v Ryazanskoy oblasti za yanvar’–dekabr’ 2021 goda. Available at: https://ryazan.gks.ru/folder/47978. Accessed: 2021 July 01.

[2] Демографическая ситуация в Рязанской области за январь– декабрь 2021 года. Доступно по: https://ryazan.gks.ru/folder/47978. Ссылка активна на 01 июля 2021.

[3] Statistika smertnosti po dannym Rosstat. Available at: https://rosinfostat.ru/smertnost//. Accessed: 2021 July 01.

[4] Статистика смертности по данным Росстат. Доступно по: https://rosinfostat.ru/smertnost//. Ссылка активна на 01 июля 2021.

[5] The top 10 causes of death. Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed: 2021 July 01.

[6] The top 10 causes of death. Доступно по: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Ссылка активна на 01 июля 2021.

[7] Fillenbaum G, Pieper CF, Cohen HJ, et al. Comorbidity of five chronic health conditions in elderly community residents: determinants and impact on mortality. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2000;55(2):M84–98. doi: 10.1093/gerona/55.2.m84

[8] Fillenbaum G., Pieper C.F., Cohen H.J., et al. Comorbidity of five chronic health conditions in elderly community residents: determinants and impact on mortality // The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2000. Vol. 55, № 2. P. M84–M98. doi: 10.1093/gerona/55.2.m84

[9] Zekry D, Valle BHL, Lardi C, et al. Geriatrics index of comorbidity was the most accurate predictor of death in geriatric hospital among six comorbidity scores. Journal of Clinical Epidemiology. 2010;63(9):1036–44. doi: 10.1016/j.jclinepi.2009.11.013

[10] Zekry D., Valle B.H.L., Lardi C., et al. Geriatrics index of comorbidity was the most accurate predictor of death in geriatric hospital among six comorbidity scores // Journal of Clinical Epidemiology. 2010. Vol. 63, № 9. P. 1036–1044. doi: 10.1016/j.jclinepi.2009.11.013

[11] Larina VN, Bart BYa, Karpenko DG, et al. Polymorbidity and its association with the unfavorable course of chronic heart failure in outpatients aged 60 years and older. Kardiologiia. 2019;59(12S):25–36. (In Russ). doi: 10.18087/cardio.n431

[12] Ларина В.Н., Барт Б.Я., Карпенко Д.Г., и др. Полиморбидность и ее связь с неблагоприятным течением хронической сердечной недостаточности у амбулаторных больных в возрасте 60 лет и старше // Кардиология. 2019. Т. 59, № 12S. С. 25–36. doi: 10.18087/cardio.n431

[13] Malchikova SV, Maksimchuk-Kolobova NS, Kazakovtseva MV. Comorbidity in elderly patients with atrial fibrillation affects the “costofillness”. Farmakoekonomika. Modern Pharmacoeconomic and Pharmacoepidemiology. 2019;12(3):191–9. (In Russ). doi: 10.17749/2070-4909.2019.12.3.191-199

[14] Мальчикова С.В., Максимчук–Колобова Н.С., Казаковцева М.В. Влияние полиморбидности у пожилых больных с фибрилляцией предсердий на «стоимость болезни» // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2019. Т. 12, № 3. С. 191–199. doi: 10.17749/2070-4909.2019.12.3.191-199

[15] Khominets VV. Obshchiy analiz smertnosti v Ryazanskoy oblasti 12 mesyatsev 2019 goda. Available at: https://tfoms-rzn.ru/images/files/koord_sovet/2020/3/1.pdf. Accessed: 2021 July 01.

[16] Хоминец В.В. Общий анализ смертности в Рязанской области 12 месяцев 2019 года. Доступно по: https://tfoms-rzn.ru/images/files/koord_sovet/2020/3/1.pdf. Ссылка активна на 01 июля 2021.

[17] Yakushin SS, Filippov EV. The main directions of the primary prevention of cardiovascular diseases. Nauka Molodykh (Eruditio Juvenium). 2014;(4):55–68. (In Russ).

[18] Якушин С.С., Филиппов Е.В. Основные направления первичной профилактики сердечно-сосудистых заболеваний // Наука молодых (Eruditio Juvenium). 2014. № 4. С. 55–68.

[19] Parshikova EN, Filippov EV. Mortality from all causes in patients with myocardial infarction with elevation of ST segment depending on the type of reperfusion therapy (data of Ryazan region, 2018–2020). I.P. Pavlov Russian Medical Biological Herald. 2020;28(4):479–87. (In Russ). doi: 10.23888/PAVLOVJ2020284479-487

[20] Паршикова Е.Н., Филиппов Е.В. Смертность от всех причин у пациентов с инфарктом миокарда с подъемом сегмента st в зависимости от типа реперфузионной терапии (данные Рязанской области, 2018–2020 гг. // Российский медико-биологический вестник имени академика И.П. Павлова. 2020. Т. 28, № 4. С. 479–487. doi: 10.23888/PAVLOVJ2020284479-487

[21] Wu J, Mamas MA, Mohamed MO, et al. Place and causes of acute cardiovascular mortality during the COVID-19 pandemic. Heart. 2021;107(2):113–9. doi: 10.1136/heartjnl-2020-317912

[22] Wu J., Mamas M.A., Mohamed M.O., et al. Place and causes of acute cardiovascular mortality during the COVID-19 pandemic // Heart. 2021. Vol. 107, № 2. P. 113–119. doi: 10.1136/heartjnl-2020-317912

[23] Butt JH, Fosbøl EL, Gerds TA, et al. All-Cause Mortality and Location of Death in Patients With Established Cardiovascular Disease Before, During, and After the COVID-19 Lockdown: A Danish Nationwide Cohort Study. European Heart Journal. 2021;42(15):1516–23. doi: 10.1093/eurheartj/ehab028

[24] Butt J.H., Fosbøl E.L., Gerds T.A., et al. All-Cause Mortality and Location of Death in Patients With Established Cardiovascular Disease Before, During, and After the COVID-19 Lockdown: A Danish Nationwide Cohort Study // European Heart Journal. 2021. Vol. 42, № 15. P. 1516–1523. doi: 10.1093/eurheartj/ehab028

[25] Alsallakh MA, Sivakumaran S, Kennedy S, et al. Impact of COVID-19 lockdown on the incidence and mortality of acute exacerbations of chronic obstructive pulmonary disease: national interrupted time series analyses for Scotland and Wales. BMC Medicine. 2021;19(1):124. doi: 10.1186/s12916-021-02000-w

[26] Alsallakh M.A., Sivakumaran S., Kennedy S., et al. Impact of COVID-19 lockdown on the incidence and mortality of acute exacerbations of chronic obstructive pulmonary disease: national interrupted time series analyses for Scotland and Wales // BMC Medicine. 2021. Vol. 19, № 1. P. 124. doi: 10.1186/s12916-021-02000-w

[27] Vremennyye metodicheskiye rekomendatsii. Profilaktika, diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID-19). Versiya 11 (07.05.2021). Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/055/735/original/B%D0%9C%D0%A0_COVID-19.pdf. Accessed: 2021 July 01.

[28] Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 11 (07.05.2021). Доступно по: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/055/735/original/B%D0%9C%D0%A0_COVID-19.pdf. Ссылка активна на 01 июля 2021.